BIEBER DERMATOLOGY CONSULTING

Selected recent publications relevant for drug development

2026

Bieber T, Lauffer F. From Sprinters to Marathoners: Rethinking Therapeutic Speed and Disease Modification in Atopic Dermatitis. Allergy. 2026;81(7):2565-7.

Bieber T, Maintz L, Phad GE, Bruggen MC. From Disease Control to Disease Modification: The Atopic Dermatitis Disease Activity Index. Allergy. 2026;81(2):577-9.

Dumycz K, Welchowski T, Deng Y, Schnautz S, Maintz L, Royeck S, et al. Circulating MicroRNA-146a-5p and MicroRNA-143-3p in Atopic Dermatitis-Atopic Comorbidities Matter. Allergy. 2026.

Simpson EL, Paller AS, Palomares O, Bieber T. Defining the Potential for Disease Modification in Atopic Dermatitis. Am J Clin Dermatol. 2026;27(5):879-85.

Sher ER, Golant A, de Bruin-Weller M, Carrascosa JM, Mehta V, Bieber T, et al. Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities. Ann Allergy Asthma Immunol. 2026;136(5):565-71.

Bieber T, Bochner BS, Boyce JA, Kabashima K, Barrett N, Holloway JW, et al. Highlights from the 2025 Symposium of the Collegium Internationale Allergologicum. J Allergy Clin Immunol. 2026;158(2):383-7.

Blauvelt A, Bieber T, Weidinger S, Chovatiya R, Rahawi K. Letter to the editor submitted in response to 'Are potential remittive properties of OX-40 inhibitors something to be excited about?'. J Dermatolog Treat. 2026;37(1):2654930.

Guttman-Yassky E, Bieber T, Kabashima K, Gutermuth J, Weidinger S, Wollenberg A, et al. Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2026;37(1):2672328.

Silverberg JI, Bieber T, Eyerich K, Armstrong AW, Nickoloff BJ, Natalie CR, et al. Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis. J Dermatolog Treat. 2026;37(1):2636417.

Bieber T. Reassessing the OX40/OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program. J Eur Acad Dermatol Venereol. 2026;40(8):1286-7.

Merola JF, Childs BA, Bartley BR, Bissonnette R, Bieber T, Guttman-Yassky E, et al. International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement. JAMA dermatology. 2026;162(6):631-9.

Silverberg JI, Rosmarin D, Bieber T, Chovatiya R, Gooderham M, Gkalpakiotis S, et al. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. Lancet. 2026;408(10557):833-46.

2025

Simpson E, Fernandez-Penas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, et al. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). Adv Ther. 2025;42(1):132-43.

Deng Y, Leib N, Schnautz S, Benfadal S, Oldenburg J, Bieber T, et al. Langerhans Cell Modulation in Atopic Dermatitis Is TLR2/SOCS1-Dependent and JAK Inhibitor-Sensitive. Allergy. 2025;80(9):2586-99.

Fehr D, Huynh-Tran VH, Maintz L, Niederseer D, Ameri M, Dreher A, et al. Deciphering the Connection Between Atopic Dermatitis and Cardiovascular Diseases: Analysis of Clinical Associations and Cardiometabolic Proteins. Allergy. 2025;80(8):2187-200.

Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025;26(6):1003-16.

Bieber T. The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification. Ann Allergy Asthma Immunol. 2025;134(2):144-50.

Sher ER, Golant A, de Bruin-Weller M, Carrascosa JM, Mehta V, Bieber T, et al. Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities. Ann Allergy Asthma Immunol. 2025.

Schwarting SK, Bieber T, Davies DR, Aus dem Siepen F, Schwarting J, Grabmaier U, et al. Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail. 2025;18(4):e011796.

Tiraboschi G, Papp K, Bieber T, Weidinger S, Beck L, Lee CH, et al. Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis. CPT Pharmacometrics Syst Pharmacol. 2025;14(12):2161-72.

Silverberg JI, Bieber T, Paller AS, Beck L, Kamata M, Puig L, et al. Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy. Dermatology and therapy. 2025;15(3):615-33.

Simpson EL, Silverberg JI, Geng B, Carrascosa JM, Bieber T, Brunner PM, et al. Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis? Dermatology and therapy. 2025;15(11):3391-407.

Guttman-Yassky E, Rosmarin D, de Bruin-Weller M, Weidinger S, Bieber T, Hong HC, et al. The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol. 2025;92(5):1024-31.

Pan Y, Hochgerner M, Cichon MA, Benezeder T, Bieber T, Wolf P. Langerhans cells: Central players in the pathophysiology of atopic dermatitis. J Eur Acad Dermatol Venereol. 2025;39(2):278-89.

Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025;39(9):1537-66.

2024

Alvarenga JM, Bieber T, Torres T. Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. 2024;84(11):1379-94.

Bieber T. The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification. Ann Allergy Asthma Immunol. 2024. 10.1016/j.anai.2024.09.022

Bieber T. Will deciphering the epidermal 'menage a trois' lead to predictive biomarkers for childhood atopic dermatitis? J Eur Acad Dermatol Venereol. 2024;38(9):1679-80.

Bissonnette R, Simpson E, Eichenfield LF, Guttman-Yassky E, Silverberg JI, Beck LA, et al. The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council. J Eur Acad Dermatol Venereol. 2024;38(3):e291-e5.

D'Erme AM, Fidanzi C, Bevilacqua M, Bieber T, Tuoni C, Paolicchi A, et al. Cord Blood Serum Levels of IL-31 and CCL17, Cutaneous Markers, and Development of Atopic Dermatitis. JAMA Dermatol. 2024;160(10):1112-5.

Muller S, Maintz L, Bieber T. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy. 2024; 79(6):1501-1515.

Muller S, Welchowski T, Schmid M, Maintz L, Herrmann N, Wilsmann-Theis D, et al. Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the "Flip-Flop" phenomenon). Allergy. 2024;79(1):164-73.

Pan Y, Hochgerner M, Cichon MA, Benezeder T, Bieber T, Wolf P. Langerhans cells: Central players in the pathophysiology of atopic dermatitis. J Eur Acad Dermatol Venereol. 2024.
Park CO, Kim SM, Lee KH, Bieber T. Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review. EBioMedicine. 2024;103:105121.

Silverberg JI, Rosmarin D, Chovatiya R, Bieber T, Schleicher S, Beck L, et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat Commun. 2024;15(1):9230.

Simpson E, Fernandez-Penas P, de Bruin-Weller M, Lio PA, Chu CY, Ezzedine K, et al. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). Adv Ther. 2024.

Solitano V, Facheris P, Petersen M, D'Amico F, Ortoncelli M, Aletaha D, et al. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study. Autoimmun Rev. 2024;23(3):103504.

Traidl-Hoffmann C, Afghani J, Akdis CA, Akdis M, Aydin H, Barenfaller K, et al. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration. Allergy. 2024;79(10):2605-24.

2023

Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662-80.

Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L, et al. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol. 2023;48(8):881-8.

Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740-8.

Kolkhir P, Akdis CA, Akdis M, Bachert C, Bieber T, Canonica GW, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743-67.

Maintz L, Schmitz MT, Herrmann N, Muller S, Havenith R, Brauer J, et al. Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood. Allergy. 2023;78(8):2181-201.

Simpson EL, Guttman-Yassky E, Eichenfield LF, Boguniewicz M, Bieber T, Schneider S, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. Allergy. 2023;78(11):2875-91.

Solitano V, Facheris P, Petersen M, D'Amico F, Ortoncelli M, Aletaha D, et al. Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study. Autoimmun Rev. 2023;23(3):103504.

Weidinger S, Bieber T, Cork MJ, Reich A, Wilson R, Quaratino S, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189(5):531-9.

Wollenberg A, Thyssen JP, Bieber T, Chan G, Kerkmann U. A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(10):2041-6.

Bissonnette R, Simpson E, Eichenfield LF, Guttman-Yassky E, Silverberg JI, Beck LA, et al. The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council. J Eur Acad Dermatol Venereol. 2023.

2022

Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21-40.

Bieber T, Paller AS, Kabashima K, Feely M, Rueda MJ, Ross Terres JA, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereol. 2022;36(9):1432-49.

Maintz L, Bieber T, Simpson HD, Demessant-Flavigny AL. From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine. J Pers Med. 2022;12(6).

Muller S, Bieber T, Stander S. Therapeutic potential of biologics in prurigo nodularis. Expert Opin Biol Ther. 2022;22(1):47-58.

Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-31.

BIEBER
DERMATOLOGY
CONSULTING

2021

Bieber T. AhR Modulating Agent for the Topical Therapy of Plaque Psoriasis. N Engl J Med. 2021;385(24):2295-6.

Bieber T, Simpson EL, Silverberg JI, Thaci D, Paul C, Pink AE, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384(12):1101-12.

Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169-81.

Klaeschen AS, Numm TJ, Herrmann N, Leib N, Maintz L, Sakai T, et al. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis. J Allergy Clin Immunol. 2021;147(6):2202-12 e8.

Maintz L, Welchowski T, Herrmann N, Brauer J, Klaschen AS, Fimmers R, et al. Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult Patients. JAMA Dermatol. 2021;157(12):1414-24.